Drug profile · INN
rasagiline mesylate
RASAGILINE MESYLATE
rasagiline mesylate (RASAGILINE MESYLATE) is a monoamine oxidase b inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — rasagiline mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 9
- Data quality
- 0.89
Quick answer
rasagiline mesylate (RASAGILINE MESYLATE) is a monoamine oxidase b inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Monoamine oxidase B inhibitor
Primary target: Amine oxidase [flavin-containing] B
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is rasagiline mesylate?
rasagiline mesylate (RASAGILINE MESYLATE) is a monoamine oxidase b inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rasagiline mesylate?
RASAGILINE MESYLATE is a marketed brand name for rasagiline mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rasagiline mesylate?
rasagiline mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.